Pharmacokinetics and tolerability of LIQ861, a novel dry-powder formulation of treprostinil

Pharmacokinetics and tolerability of LIQ861, a novel dry-powder formulation of treprostinil

A dry-powder inhaled formulation of treprostinil (LIQ861) produced using PRINT® technology offers a substantial advantage over current nebulized therapy. Treprostinil is a synthetic prostacyclin analogue that is currently approved for inhalation administration to patients with pulmonary arterial hyp...

Full description

Bibliographic Details
Main Authors:	Robert Roscigno, Toby Vaughn, Stephanie Anderson, William Wargin, Thomas Hunt, Nicholas S. Hill
Format:	Article
Language:	English
Published:	SAGE Publishing 2020-11-01
Series:	Pulmonary Circulation
Online Access:	https://doi.org/10.1177/2045894020971509

Similar Items

Long-term study of oral treprostinil to treat pulmonary arterial hypertension: dosing, tolerability, and pharmacokinetics
by: R. James White, et al.
Published: (2020-12-01)

Sodium/liq. NH^^cleavage of l-crychine
by: LIN, JIA-YIN, et al.
Published: (1989)

Characterisation of cough evoked by inhaled treprostinil and treprostinil palmitil
by: Richard W. Chapman, et al.
Published: (2021-02-01)

Decreto número 861
by: Ciencia y Sociedad CyS
Published: (1983-12-01)

Treprostinil for pulmonary hypertension
by: Nika Skoro-Sajer, et al.
Published: (2008-06-01)

BREEZE: Open-label clinical study to evaluate the safety and tolerability of treprostinil inhalation powder as Tyvaso DPI™ in patients with pulmonary arterial hypertension
by: Bajwa, A.A, et al.
Published: (2022)

MDH DAVLATLARIDA MUALLIFLIK HUQUQI TARIXI BILAN BOG’LIQ AYRIM MULOHAZALAR
by: Javlonbek Begaliyev, et al.
Published: (2020-10-01)

Inhaled treprostinil: a therapeutic review
by: Channick RN, et al.
Published: (2012-01-01)

Environmental Management Plan for the Chemical Engineering Laboratory (LIQ) of the National University of Colombia, Bogotá
by: Javier Gama Chávez, et al.
Published: (2004-01-01)

Pharmacokinetics and tolerability of inhaled levodopa from a new dry-powder inhaler in patients with Parkinson’s disease
by: Marianne Luinstra, et al.
Published: (2019-06-01)

Experiences with treprostinil in the treatment of pulmonary arterial hypertension
by: Amanda R. Stream, et al.
Published: (2012-10-01)

Successful management of an inadvertent excessive treprostinil overdose
by: Hohenforst-Schmidt W, et al.
Published: (2013-03-01)

Treprostinil Iontophoresis In Idiopathic Pulmonary Arterial Hypertension
by: Tonelli, Adriano R.
Published: (2015)

Impact of four times daily dosing of oral treprostinil on tolerability and daily dose achieved in pulmonary hypertension
by: James C. Coons, et al.
Published: (2017-11-01)

Tolerability and Pharmacokinetic Evaluation of Inhaled Dry Powder Tobramycin Free Base in Non-Cystic Fibrosis Bronchiectasis Patients.
by: Marcel Hoppentocht, et al.
Published: (2016-01-01)

Development of dry powder formulations of proteins for inhalation
by: Depreter, Flore
Published: (2012)

The potential for inhaled treprostinil in the treatment of pulmonary arterial hypertension
by: Tobias Gessler, et al.
Published: (2011-06-01)

In vivo pharmacokinetic study of remdesivir dry powder for inhalation in hamsters
by: Sawittree Sahakijpijarn, et al.
Published: (2021-12-01)

Liq_ccRCC: Identification of Clear Cell Renal Cell Carcinoma Based on the Integration of Clinical Liquid Indices
by: Jianhong Zhao, et al.
Published: (2021-01-01)

Fundus Examination of 23,861 Newborns by Digital Imaging in Ningbo
by: Delin Liu, et al.
Published: (2021-01-01)

Framtagande av ny höjdmätningsmetod till försvarets antennhiss 861
by: Åhs, Karl-Johan
Published: (2012)

Oral treprostinil use in children: a multicenter, observational experience
by: Usama Kanaan, et al.
Published: (2019-07-01)

Dosing characteristics of oral treprostinil in real-world clinical practice
by: Vijay P. Balasubramanian, et al.
Published: (2018-07-01)

Miniaturised devices for dry powder handling in drug formulation
by: Vilkner, Torsten
Published: (2005)

Development of Triazole-based Dry Powder Formulations for Inhalation
by: Merlos, Romain
Published: (2019)

Development of High Efficiency Dry Powder Inhalers for Use with Spray Dried Formulations
by: Farkas, Dale
Published: (2017)

Spray Drying for the Preparation of Nanoparticle-Based Drug Formulations as Dry Powders for Inhalation
by: Maria Malamatari, et al.
Published: (2020-07-01)

PREPARATION OF ISONIAZID AS DRY POWDER FORMULATIONS FOR INHALATION BY PHYSICAL MIXING AND SPRAY DRYING
by: SOMCHAI SAWATDEE, et al.
Published: (2006-01-01)

The office of qadi in the early Abbasid caliphate (132-247/750-861)
by: Kasassbeh, Hussein F. S.
Published: (1990)

The struggle for power in the 'Abbasid Caliphate between 247/861 and 256/870
by: Al-Tikriti, Bahjat Kamil
Published: (1972)

Correction to Lancet Glob Health 2019; 7: e861–71
Published: (2021-06-01)

Intravenous treprostinil via an implantable pump in pediatric pulmonary arterial hypertension
by: Susanna Desole, et al.
Published: (2018-12-01)

Oral treprostinil in transition or as add-on therapy in pediatric pulmonary arterial hypertension
by: D. Dunbar Ivy, et al.
Published: (2019-07-01)

Implantable system for treprostinil: a real-world patient experience study
by: Shelley Shapiro, et al.
Published: (2020-04-01)

Characterization and Formulation of Isoniazid for High-Dose Dry Powder Inhalation
by: Imco Sibum, et al.
Published: (2019-05-01)

Spray-Dried Powders for Inhalation : Particle Formation and Formulation Concepts
by: Elversson, Jessica
Published: (2005)

Effects of particle surface modifications on dry powder formulation performances
by: Schueller, Laurent
Published: (2005)

Rolle reassembled: Booklet production, single-author anthologies, and the making of bodley 861
by: Kraebel, A.
Published: (2019)

Clinical Utility of Treprostinil and Its Overall Place in the Treatment of Pulmonary Arterial Hypertension
by: Shireen Mirza, et al.
Published: (2012-07-01)

Transition from selexipag to oral treprostinil in a patient with pulmonary arterial hypertension
by: Ifeoma Oriaku, et al.
Published: (2020-03-01)